Elevance Health, Inc. (NYSE:ELV) Shares Acquired by Hyman Charles D

Hyman Charles D increased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 0.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 13,928 shares of the company’s stock after purchasing an additional 51 shares during the period. Hyman Charles D’s holdings in Elevance Health were worth $6,568,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ELV. International Assets Investment Management LLC boosted its position in Elevance Health by 45,888.1% in the 4th quarter. International Assets Investment Management LLC now owns 255,694 shares of the company’s stock valued at $1,205,750,000 after buying an additional 255,138 shares during the period. Assenagon Asset Management S.A. grew its stake in Elevance Health by 212.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 366,833 shares of the company’s stock worth $159,726,000 after purchasing an additional 249,533 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in Elevance Health by 57.7% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 640,905 shares of the company’s stock worth $279,063,000 after purchasing an additional 234,439 shares during the period. Schroder Investment Management Group raised its position in Elevance Health by 18.2% in the 3rd quarter. Schroder Investment Management Group now owns 1,330,883 shares of the company’s stock valued at $579,493,000 after purchasing an additional 204,715 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its stake in shares of Elevance Health by 59.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 491,504 shares of the company’s stock valued at $214,011,000 after buying an additional 182,889 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Activity

In related news, EVP Felicia F. Norwood sold 14,111 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now directly owns 31,460 shares of the company’s stock, valued at $16,791,460.40. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $500.00, for a total transaction of $376,500.00. Following the transaction, the director now owns 9,109 shares of the company’s stock, valued at $4,554,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Felicia F. Norwood sold 14,111 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now owns 31,460 shares of the company’s stock, valued at approximately $16,791,460.40. The disclosure for this sale can be found here. Corporate insiders own 0.29% of the company’s stock.

Elevance Health Stock Performance

Shares of ELV traded up $6.13 during mid-day trading on Tuesday, reaching $536.06. 692,867 shares of the company’s stock were exchanged, compared to its average volume of 1,045,833. The business’s fifty day simple moving average is $514.57 and its 200-day simple moving average is $490.26. The stock has a market capitalization of $124.59 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 1.16 and a beta of 0.79. Elevance Health, Inc. has a 52-week low of $412.00 and a 52-week high of $542.07. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.37 and a quick ratio of 1.37.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The firm had revenue of $42.27 billion during the quarter, compared to analysts’ expectations of $42.49 billion. During the same quarter in the prior year, the business earned $9.46 EPS. Elevance Health’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Elevance Health, Inc. will post 37.26 earnings per share for the current year.

Elevance Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be paid a $1.63 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $6.52 annualized dividend and a dividend yield of 1.22%. Elevance Health’s dividend payout ratio (DPR) is currently 24.64%.

Analyst Ratings Changes

A number of analysts recently weighed in on ELV shares. Royal Bank of Canada upped their target price on shares of Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research note on Friday, April 19th. Wells Fargo & Company boosted their target price on shares of Elevance Health from $557.00 to $600.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Truist Financial reissued a “buy” rating and issued a $600.00 target price (up previously from $580.00) on shares of Elevance Health in a report on Friday, April 19th. Barclays upped their price objective on Elevance Health from $584.00 to $621.00 and gave the stock an “overweight” rating in a research report on Friday, April 19th. Finally, UBS Group raised their target price on Elevance Health from $585.00 to $605.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $587.42.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.